Santhera's Exclusive Distribution of Vamorolone (AGAMREE®) in Central and Eastern Europe
Monday, 9 September 2024, 22:06
Santhera Pharmaceuticals Partners with GENESIS Pharma
Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) in Central and Eastern Europe. This strategic alliance is set to enhance the availability of this critical therapeutic option to patients suffering from rare inflammatory conditions.
Details of the Distribution Agreement
- Vamorolone is designed to provide effective anti-inflammatory benefits with reduced side effects.
- With this partnership, both companies aim to streamline the distribution process and ensure that AGAMREE® reaches those in need.
- This collaboration signifies a major step in expanding treatment accessibility for patients in these regions.
Significance of Vamorolone in Treatment
- Vamorolone has shown promise in clinical trials, demonstrating a potential to revolutionize treatment regimens.
- The medication's unique properties may offer advantages over traditional corticosteroids.
- This partnership allows both Santhera and GENESIS Pharma to leverage their expertise in enhancing patient care.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.